Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure
Heart Rhythm · 2025
DOI: 10.1016/j.hrthm.2024.08.034 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Heart Rhythm, 2025. Verfasst von Zixu Zhao und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases, Beij…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Heart Failure, Registries. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Beijing Hospital Authority.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: The impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on atrial fibrillation (AF) recurrence outcomes and adverse cardiovascular outcomes in heart failure (HF) patients after AF ablation is unknown. OBJECTIVE: We investigated whether SGLT2i reduces the risk of AF recurrence and adverse cardiovascular outcomes in HF patients after AF ablation. METHODS: HF patients with AF undergoing catheter ablation between January 2017 and December 2022 from the China-AF Registry were included. Patients were stratified into 2 groups on the basis of the use of SGLT2i at discharge and were 1:1 matched by propensity score, with SGLT2i using (n = 368) and non-SGLT2i using (n = 368) in each group. The primary outcome was AF recurrence after a 3-month blanking period. RESULTS: During a total of 1315 person-years of follow-up, AF recurred in 83 patients (22.6%) in the SGLT2i group and 132 patients (35.8%) in the non-SGLT2i group. SGLT2i was associated with a lower risk of AF recurrence (adjusted hazard ratio, 0.56; 95% CI, 0.43-0.74; P < .001). The composite risk of cardiovascular death, thrombotic events, or cardiovascular hospitalization was significantly lower in the SGLT2i group compared with those without SGLT2i (adjusted hazard ratio, 0.58; 95% CI, 0.41-0.80; P = .001). Although there was a trend toward benefit, the differences in all-cause mortality, cardiovascular death, or thrombotic events were insignificant between the 2 groups. CONCLUSION: The use of SGLT2i was associated with a lower risk of AF recurrence and the composite outcome of cardiovascular death, thrombotic events, or cardiovascular hospitalization after catheter ablation for AF in patients with HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases, Beijing, China.
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases, Beijing, China. Electronic address: superj@zju.edu.cn.
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases, Beijing, China; Heart Health Research Center, Beijing, China.
- Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia, China. Electronic address: hlp@139.com.
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases, Beijing, China. Electronic address: chshma@vip.sina.com.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Beijing Hospital Authority
Zitieren
APA
Zhao, Z., Wang, Y., Jiang, C., Yang, Z., Zhang, J., Lai, Y., Wang, J., Li, S., Peng, X., Li, M., Li, E., Guo, H., Li, J., Kong, X., He, L., Zuo, S., Guo, X., Li, S., Liu, N., …, & Ma, C. (2025). Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2024.08.034
Vancouver
Zhao Z, Wang Y, Jiang C, Yang Z, Zhang J, Lai Y, et al. Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2024.08.034
BibTeX
@article{Zhao2025,
author = {Zhao, Zixu and Wang, Yiping and Jiang, Chao and Yang, Zejun and Zhang, Jingrui and Lai, Yiwei and Wang, Jue and Li, Sitong and Peng, Xiaodong and Li, Mingxiao and Li, Enze and Guo, Hang and Li, Jiahe and Kong, Xiangyi and He, Liu and Zuo, Song and Guo, Xueyuan and Li, Songnan and Liu, Nian and Tang, Ribo and Sang, Caihua and Long, Deyong and Du, Xin and He, Liping and Dong, Jianzeng and Ma, Changsheng},
title = {Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure},
journal = {Heart Rhythm},
year = {2025},
doi = {10.1016/j.hrthm.2024.08.034}
}
EUVIMED